Chemokine-binding proteins for treating congestive heart failure
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 7, 2002
app pub date -
May 2, 2002
filing date -
May 4, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Chemokine-binding proteins are administered as a treatment for congestive heart failure and related disorders. Evidence indicates that CC chemokines are a factor in the disease pathogenesis; by binding to receptors on heart muscle cells, the chemokines may, through a G-protein-coupled transduction system, increase the concentration of free calcium ions in the cytoplasm. This disrupts the normal calcium cycle required for muscle contraction and relaxation, and is a likely mechanism for development of congestive heart failure. Suitable proteins include poxyirus-encoded CC chemokine inhibitors and promiscuous chemokine receptors; these proteins bind to a number of different CC chemokines with high affinity but generally do not bind to other subfamilies of chemokines.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully